A collaborative study between researchers from the Yong Loo Lin School of Medicine, National...
Author - David Miller
Enhertu Approved as First HER2-Directed Therapy for Patients...
27 January 2025 — AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has...
FDA Approves Grafapex (treosulfan) Preparative Regimen for...
On January 22, 2025, Medexus was informed that the FDA approved Grafapex, an alkylating agent, with...
Spravato (esketamine) Approved in the U.S. as the First and Only...
Titusville, New Jersey, January 21, 2025 – Johnson & Johnson (NYSE: JNJ) announced today the...
FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients...
WILMINGTON, Del.– January 17, 2025 — Datroway (datopotamab deruxtecan-dlnk) has been...
Calquence Plus Chemoimmunotherapy Approved in the U.S. for...
17 January 2025 — AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine...
FDA Approves Lumakras (sotorasib) in Combination with Vectibix...
THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that...
FDA Approves Lilly’s Omvoh (mirikizumab-mrkz) for...
INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today...
Incyte and Syndax Announce U.S. Food and Drug Administration...
WILMINGTON, Del. and WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ — Incyte (Nasdaq:INCY) and...
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)...
PRINCETON, N.J.–(BUSINESS WIRE) December 27, 2024 — Bristol Myers Squibb (NYSE: BMY)...